BACKGROUND: While marijuana use is prevalent among persons with HIV (PWH), few studies have examined the relationship between marijuana use and HIV treatment outcomes independent of alcohol and other drug use. METHODS: We conducted a prospective cohort study to examine the relationships between frequency of marijuana use and antiretroviral therapy (ART) adherence and viral suppression in patients enrolled in the Johns Hopkins HIV Clinical Cohort between September 2013 through November 2015 (N=1377). We categorized marijuana use as no use, none in the last 3months, monthly use or less, weekly/daily. Our outcomes of interest were use of ART, ≥90 ART adherence, and viral suppression (HIV1-RNA<200 copies). We conducted multivariable analyses to examine associations between the frequency of marijuana use and our treatment outcomes, using generalized estimating equations to account for repeated measures. Other independent variables of interest included alcohol use, other drug use, and depressive symptoms. Analyses were adjusted for age, race, sex and HIV acquisition risk factor. RESULTS: In multivariable analyses we found no statistically significant association between frequency of marijuana use and our treatment outcomes. Alcohol use, other drug use and depressive symptoms were associated with lower odds of ART adherence and viral suppression. CONCLUSIONS: In this sample of PWH in care, frequency of marijuana use independent of other substance use does not appear to be associated with negative HIV treatment outcomes. Our results indicate that unlike alcohol, other substances and depression, marijuana use may not be a barrier to the effective treatment of HIV.
BACKGROUND: While marijuana use is prevalent among persons with HIV (PWH), few studies have examined the relationship between marijuana use and HIV treatment outcomes independent of alcohol and other drug use. METHODS: We conducted a prospective cohort study to examine the relationships between frequency of marijuana use and antiretroviral therapy (ART) adherence and viral suppression in patients enrolled in the Johns Hopkins HIV Clinical Cohort between September 2013 through November 2015 (N=1377). We categorized marijuana use as no use, none in the last 3months, monthly use or less, weekly/daily. Our outcomes of interest were use of ART, ≥90 ART adherence, and viral suppression (HIV1-RNA<200 copies). We conducted multivariable analyses to examine associations between the frequency of marijuana use and our treatment outcomes, using generalized estimating equations to account for repeated measures. Other independent variables of interest included alcohol use, other drug use, and depressive symptoms. Analyses were adjusted for age, race, sex and HIV acquisition risk factor. RESULTS: In multivariable analyses we found no statistically significant association between frequency of marijuana use and our treatment outcomes. Alcohol use, other drug use and depressive symptoms were associated with lower odds of ART adherence and viral suppression. CONCLUSIONS: In this sample of PWH in care, frequency of marijuana use independent of other substance use does not appear to be associated with negative HIV treatment outcomes. Our results indicate that unlike alcohol, other substances and depression, marijuana use may not be a barrier to the effective treatment of HIV.
Authors: Heidi M Crane; Mary E McCaul; Geetanjali Chander; Heidi Hutton; Robin M Nance; Joseph A C Delaney; Joseph O Merrill; Bryan Lau; Kenneth H Mayer; Michael J Mugavero; Matthew Mimiaga; James H Willig; Greer A Burkholder; Daniel R Drozd; Rob J Fredericksen; Karen Cropsey; Richard D Moore; Jane M Simoni; W Christopher Mathews; Joseph J Eron; Sonia Napravnik; Katerina Christopoulos; Elvin Geng; Michael S Saag; Mari M Kitahata Journal: AIDS Behav Date: 2017-07
Authors: Panagiotis Vagenas; Marwan M Azar; Michael M Copenhaver; Sandra A Springer; Patricia E Molina; Frederick L Altice Journal: Curr HIV/AIDS Rep Date: 2015-12 Impact factor: 5.071
Authors: Maria Leticia R Ikeda; Nemora T Barcellos; Paulo R Alencastro; Fernando H Wolff; Leila B Moreira; Miguel Gus; Ajacio B M Brandão; Flavio D Fuchs; Sandra C Fuchs Journal: PLoS One Date: 2016-06-30 Impact factor: 3.240
Authors: Chukwuemeka N Okafor; Michael W Plankey; David Goodman-Meza; Michael Li; Karla J Bautista; Hector Bolivar; Tien C Phyllis; Todd T Brown; Steven J Shoptaw Journal: Drug Alcohol Depend Date: 2020-02-20 Impact factor: 4.492
Authors: Patrick S Sullivan; Justin Knox; Jeb Jones; Jennifer Taussig; Mariah Valentine Graves; Greg Millett; Nicole Luisi; Eric Hall; Travis H Sanchez; Carlos Del Rio; Colleen Kelley; Eli S Rosenberg; Jodie L Guest Journal: J Int AIDS Soc Date: 2021-04 Impact factor: 5.396
Authors: Jessica S Merlin; Dustin Long; William C Becker; Edward R Cachay; Katerina A Christopolous; Kasey R Claborn; Heidi M Crane; Eva Jennifer Edelman; Travis I Lovejoy; William Christopher Mathews; Benjamin J Morasco; Sonia Napravnik; Connall OʼCleirigh; Michael S Saag; Joanna L Starrels; Robert Gross; Jane M Liebschutz Journal: J Acquir Immune Defic Syndr Date: 2019-06-01 Impact factor: 3.731
Authors: Chukwuemeka N Okafor; Michael W Plankey; Michael Li; Xinguang Chen; Pamela J Surkan; Steve Shoptaw; Eileen Martin; Ronald Cohen; Ned Sacktor; Robert L Cook Journal: Subst Use Misuse Date: 2019-01-30 Impact factor: 2.164
Authors: Sarah M Jabour; Geetanjali Chander; Kristin A Riekert; Jeanne C Keruly; Kayla Herne; Heidi Hutton; Mary Catherine Beach; Bryan Lau; Richard D Moore; Anne K Monroe Journal: AIDS Behav Date: 2021-02-09
Authors: Angel B Algarin; Gabriela N Plazarte; Kaitlin R Sovich; Stella D Seeger; Yancheng Li; Ronald A Cohen; Catherine W Striley; Bruce A Goldberger; Yan Wang; Charurut Somboonwit; Gladys E Ibañez; Emma C Spencer; Robert L Cook Journal: JMIR Res Protoc Date: 2022-08-30